Millennium Management LLC Increases Stock Holdings in BioNTech SE Sponsored ADR $BNTX

Key Points

• Millennium Management LLC increased its ownership in BioNTech by 252.5%, acquiring an additional 390,360 shares, bringing its total to 544,970 shares worth approximately $49.6 million.
• BioNTech's stock dropped 8.7%, and the company's recent earnings report revealed a loss of ($1.60) per share, missing estimates but showing a 102.6% increase in revenue year-over-year.
• Wall Street analysts have a mixed outlook on BioNTech, with thirteen analysts$135.80.

Millennium Management LLC raised its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 252.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 544,970 shares of the company's stock after acquiring an additional 390,360 shares during the period. Millennium Management LLC owned about 0.23% of BioNTech worth $49,625,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. Baird Financial Group Inc. boosted its stake in BioNTech by 14.2% in the fourth quarter. Baird Financial Group Inc. now owns 18,589 shares of the company's stock worth $2,118,000 after purchasing an additional 2,307 shares in the last quarter. Deutsche Bank AG grew its holdings in shares of BioNTech by 2.3% during the fourth quarter. Deutsche Bank AG now owns 304,500 shares of the company's stock worth $34,698,000 after purchasing an additional 6,749 shares during the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of BioNTech during the fourth quarter worth $570,000. Integral Health Asset Management LLC lifted its stake in shares of BioNTech by 100.0% during the fourth quarter. Integral Health Asset Management LLC now owns 100,000 shares of the company's stock valued at $11,395,000 after acquiring an additional 50,000 shares during the period. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of BioNTech during the fourth quarter valued at $1,014,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Price Performance

Shares of BNTX stock traded down $7.57 on Friday, hitting $96.74. 5,152,296 shares of the company's stock were exchanged, compared to its average volume of 1,107,423. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. BioNTech SE Sponsored ADR has a 12 month low of $81.20 and a 12 month high of $131.49. The stock has a market cap of $23.26 billion, a P/E ratio of -60.46 and a beta of 1.39. The company has a 50 day moving average of $108.79 and a 200 day moving average of $103.88.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The firm had revenue of $306.46 million during the quarter, compared to the consensus estimate of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. BioNTech's revenue for the quarter was up 102.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. On average, equities research analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on BNTX. Morgan Stanley upped their price target on BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. Bank of America increased their target price on BioNTech from $126.00 to $134.00 and gave the company a "buy" rating in a research note on Tuesday, August 5th. JPMorgan Chase & Co. cut their target price on BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. Leerink Partners set a $112.00 target price on BioNTech in a research report on Monday, June 2nd. Finally, The Goldman Sachs Group initiated coverage on BioNTech in a research report on Thursday, May 29th. They set a "neutral" rating and a $110.00 price target on the stock. Thirteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, BioNTech has a consensus rating of "Moderate Buy" and a consensus target price of $135.80.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.